The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 February 2026•

1 min read

ImmunityBio Shares Surge 41% Following EU Approval for Cancer Treatment

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Shares of ImmunityBio (IBRX) experienced a massive rally, surging 41.36% to reach $8.51 following significant regulatory news from Europe. The European Commission has granted conditional marketing authorization for the company's immunotherapy drug, ANKTIVA, specifically for the treatment of bladder cancer. This approval represents a major milestone, significantly expanding the company's commercial reach within the global oncology market. Following the stock's jump, ImmunityBio's market capitalization has risen to approximately $5.9 billion, reflecting strong investor confidence. Regulatory milestones are primary catalysts for biotech stocks, often leading to substantial shifts in valuation and revenue potential. The expansion into the European market is expected to bolster the company's long-term market position and growth trajectory.